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Epidermal growth factor receptor (EGFR) is a key factor in tumorigenesis. The association between EGFR expression and prognosis
in renal cell carcinoma (RCC) is not clear. In our study of 134 RCCs, the cellular location of immunostaining was evaluated and
patients with EGFR-positive tumours with prominent membranous staining had a good prognosis. Their overall survival was
significantly longer (P¼0.004) than that of patients with either EGFR-negative tumours or with mainly cytoplasmic staining. However,
further studies on the different EGFR expression patterns in RCC are needed to clarify their role in the progression of the disease.
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The epidermal growth factor receptor (EGFR) family has been
found to play a central role in tumour progression. Ligand binding
to the EGFR, receptor dimerisation and the activation of down-
stream signalling pathways are molecular events involved in
tumorigenesis (Kim and Muller, 1999; Carpenter, 2000. High
expression of EGFR is considered to be an unfavourable prognostic
factor in patients with a variety of tumours (Lieberman et al, 1985;
Slamon et al, 1987; Neal et al, 1990), including renal cell carcinoma
(RCC) (Uhlman et al, 1995; Yoshida et al, 1997). However, there
are also studies on RCC reporting no association between EGFR
and prognosis (Hofmockel et al, 1997). In these studies, in addition
to ligand binding and immunohistochemical methods (Yoshida
et al, 1997), also Northern blot (Sargent et al, 1989) and Southern
blot (Gomella et al, 1989) analyses have been used. In the present
study, we examined the association between the location of the
EGFR immunostaining and prognosis in RCC.
MATERIALS AND METHODS
Patients
Our study population consisted of 134 consecutive patients who
underwent radical nephrectomy for RCC between 1995 and 1999 at
Tampere University Hospital. The median age of the patients (83
men and 51 women) at the time of operation was 64 years (range
35–86 years). Clinical stage was assigned using the TNM
Classification of Malignant Tumours (UICC, 1997). The median
follow-up time was 40 months, 49 months for survivors and 12
months for nonsurvivors. During the follow-up time, 40 patients
died of RCC and 17 of other causes.
Specimens
Archival formalin-fixed, paraffin-embedded RCC material was used
for the study. All tissue blocks were re-evaluated (PH), and from a
representative area for each tumour a 3-mm core was transferred to
a multi-tissue block, which was then used for further analysis. All
tumours were classified according to Heidelberg classification
(Kovacs et al, 1997) and graded according to the Fuhrman system
(Fuhrman et al, 1982) by two pathologists (HH, PM).
Immunohistochemical staining
Paraffin-embedded multi-tissue blocks were cut 4–5mmi n
thickness and mounted on precoated slides. After deparaffinisa-
tion, antigen retrieval was performed by heating the sections in a
microwave oven for 2 7min in 10mM Tris/1mM EDTA (pH 9.0)
buffer, followed by washes with water. A polyclonal rabbit anti-
EGFr variant III antibody (Zymed Laboratories, Inc., San
Francisco, CA, USA) was used for EGFR immunostaining at a
concentration of 5mgml
 1. A TechMatet 500 Plus Immunostainer
(DAKO a/s, Glostrup, Denmark) was used for the staining
procedure and a ChemMatet peroxidase/DAB detection kit
(DAKO a/s, Glostrup, Denmark) for visualisation of the antigen–
antibody complex. Sections were slightly counterstained with
haematoxylin.
Evaluation of immunohistochemical staining
The optimal titre for EGFR staining was defined as the dilution
giving clearly identifiable membrane staining and negligible Received 13 February 2003; revised 24 June 2003; accepted 8 July 2003
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ybackground on human placental samples. The intensity of the
immunostaining in RCC (scale 0–3) was multiplied by the
percentage of cells with positive staining to give a score of 0–
300. Thus scored, the positive placental control (Neal et al, 1990) in
our system gave a score of 100 (Figure 1, inset). Five staining
patterns were scored: solely (m) or predominantly (m4c)
membranous staining, solely (c) or predominantly (c4m)
cytoplasmic staining or equal (c¼m).
Statistical analysis
Associations of different staining patterns with other main
prognostic parameters were tested using Fisher’s exact test. Cox
regression analysis was used to test for differences in RCC-specific
survival. Both univariate and multivariate analyses were per-
formed. In multivariate analysis, prognostic significance was tested
for age at operation time, TNM stage, Fuhrman grade, gender and
location of EGFR staining. Deaths from causes other than RCC
were considered as censored events. An SPSS software version 11.0
was used for statistical analyses.
Ethics
The research plan was approved by the Ethical Committee of
Tampere University Hospital, and oral informed consent was
obtained from every patient.
RESULTS
Altogether, 69 of the tumours (52%) were local (T1–2, N0, M0), 27
(20%) locally advanced (T3–4, N0, M0) and 38 (28%) dissemi-
nated (T1–4, Nþ/Mþ); 122 (89%) of the tumours had
conventional type (clear cell), six (5%) papillary, two (2%)
chromophobe, two (2%) collecting duct histology. Two of the
tumours (2%) remained unclassified. By nuclear grading, four
(3%) of the tumours were classified as grade 1, 59 (44%) as grade 2,
57 (43%) as grade 3 and 14 (10%) as grade 4.
Epidermal growth factor receptor scores varied between 0 and
300, mean score was 83. In all, 73% of tumours were positive in
EGFR immunostaining with cutoff score 20. When placental
control (score 100) was used as a cutoff score, the percentage of
positive tumours was 49%. Papillary tumours had markedly
elevated scores (mean 140763) when compared to those with
clear cells (mean 79769). The distribution of EGFR immunostain-
ing was as follows: no staining 23%, m 3% (Figure 1A), m4c 11%,
m¼c 13%, c4m 25% and c 25% (Figure 1B). Stratification into
three groups was carried out: 1: no staining (23%), 2: prominent
membranous staining (27%, including cases m, m4c and m¼c)
and 3: predominantly cytoplasmic staining (50%, including cases
c4m and c). Papillary tumours all had cytoplasmic staining.
In univariate analysis for survival, predominantly membranous
staining (Group 2 in Figure 2) associates with good prognosis,
(hazard ratio (HR) 8.0; 95% CI 2.0–33.2; P¼0.004). When EGFR
expression was handled as a continuous numeric factor (score) or
divided into two classes (cutoff score 20 or 100), there was no
statistically significant association with RCC survival. In the
multivariate analysis, TNM stage was a very strong and single
significant prognostic indicator (HR 37.0; 95% CI 8.2–167.5;
Po0.001). The membranous immunostaining was not associated
with low stages 1–2 (P¼0.091, Table 1), but there was a
statistically significant association with low Fuhrman grades
(P¼0.001, Fisher’s exact test, Table 2).
DISCUSSION
In the present study, we showed the importance of the location of
EGFR immunostaining in evaluating the prognosis in an
unselected group of patients treated for RCC. The study was
carried out on unselected consecutive patients operated for RCC in
a prospective manner having a well-defined follow-up schedule.
Figure 1 Membranous (A) and cytoplasmic (B) EGFR staining of two cases of RCC and the corresponding morphology (C, D) in haematoxylin and eosin
staining. Placental control of EGFR staining is shown in the inset in B.
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yHigh expression of EGFR has been associated with advanced
stage, poor prognosis and high metastatic potential in
many human tumours (Lieberman et al, 1985; Slamon et al,
1987; Neal et al, 1990). The association between EGFR expression
and prognosis in RCC has not been established. There are
several complicating factors: the histological heterogeneity of
RCC and the individual properties of different assessment
methods. For example, the ligand binding method, which
has been held to be a sensitive method for measurement
of EGFR, measures functional properties and the technique
concentrates on membranous proteins only (Yoshida et al,
1997). Immunohistochemistry, on the other hand, offers
a simple and economical means for cellular detection of EGFR
and analysing its location in tumour cells. So far, several
immunohistochemical studies have shown that positive EGFR
staining in RCC is common and is associated with cell proliferation
(Moch et al, 1997), but its role as a prognostic factor
remains uncertain (Hofmockel et al, 1997). In the immunohisto-
chemical study by Uhlman et al (1995), membranous
EGFR expression was associated with high tumour grade,
metastatic disease and poor disease-specific survival. In
contrast to that, in our study membranotic positivity was
associated with good prognosis, while cytoplasmic or negative
EGFR staining was not. The explanation for this discrepancy is
unclear. However, in the present study, both the intensity
and location of EGFR staining in tumour cells were taken
into account when evaluating its associations with prognosis,
while in the study by Uhlman et al, there is no description of
staining pattern and differences in antibody and staining
process may partly explain different results. A similar adverse
prognostic role of cytoplasmic EGFR staining demonstrated
in our study has also been shown in squamous cell carcinoma
of the lung (Piyathilake et al, 2002). The association between
poor prognosis and cytoplasmic EGFR staining may be
due to changes in ligand–EGFR complex internalisation
and activation of associated signalling pathways in the progression
of RCC, the theory that Piyathilake et al have further strengthened
by cell culture experiments. The localisation pattern of
immunostaining has also been shown to have prognostic
value with other markers in cancer like bcl-2 expression in
malignant melanoma. In studies by Vlaykova et al (2002),
a diffuse localisation of bcl-2 expression by immunostaining was
associated with better survival than negative or focal expression in
malignant melanoma. Similarly, the aberrant cellular location of
some adhesion molecules such as alpha-catenin may result in
tumour dedifferentiation and aggressive, metastatic phenotype
(Hirvikoski et al (1998) in laryngeal carcinoma). In the present
study, the presence of immunostaining in the membranes was
associated with exceptionally good prognosis. It can be speculated
that in RCCs in which EGFR distribution in cell membranes is
maintained, the growth is probably still controlled by EGF rather
than by activation of new signalling pathways. Thus, the
distinction between two different survival groups within the
EGFR-positive RCCs, in addition to being a candidate for a simple
prognostic marker, opens up the challenging possibility of
different molecular targets for drug development for these patient
groups. The third group in our study, RCCs with totally negative
EGFR staining, may include a group of cancers in which
mechanisms other than EGF are responsible for cancer growth
and progression.
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Figure 2 Survival of RCC patients and its correlation with EGFR
localisation. Group 1: no staining, group 2: prominent membranous staining
and group 3: predominantly cytoplasmic staining.
Table 1 Crosstabulated EGFR immunostaining location classes vs stages
Stage
EGFR staining location 1 2 3 4
No staining 11 4 5 11
20.4% 26.7% 17.9% 29.7%
Membranous staining 19 12 11 4
35.2% 13.3% 39.3% 10.8%
Cytoplasmic staining 24 9 12 22
44.4% 60.0% 42.9% 59.5%
100% 100% 100% 100%
No statistical associations, P¼0.091, Fisher’s exact test.
Table 2 Crosstabulated EGFR immunostaining location classes vs
Fuhrman nuclear grades
Fuhrman nuclear grade
EGFR staining location 1 2 3 4
No staining 0 11 15 5
0.0% 18.6% 26.3% 35.7%
Membranous staining 3 25 6 2
75.0% 42.4% 10.5% 14.3%
Cytoplasmic staining 1 23 36 7
25.0% 39.0% 63.2% 50.0%
100% 100% 100% 100%
The membranous immunostaining has a statistically significant association with low
Fuhrman grades, P¼0.001, Fisher’s exact test.
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staining associates with good prognosis in RCC. However,
further studies will be needed to clarify the role of the
different EGFR patterns in development and progression of
RCC.
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